Pierre Fabre Medicament — China drug registrations and re-registration deadlines
6 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2027-12-06.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20140083 | Navelbine 酒石酸长春瑞滨注射液 | 2028-06-06 | 2027-12-06 |
| 国药准字HJ20140084 | Navelbine 酒石酸长春瑞滨注射液 | 2028-06-06 | 2027-12-06 |
| 国药准字HJ20140658 | Vinorelbine Tartrate Soft Capsule 酒石酸长春瑞滨软胶囊 | 2028-12-25 | 2028-06-25 |
| 国药准字HJ20200009 | NERLYNX 马来酸奈拉替尼片 | 2029-12-30 | 2029-06-30 |
| 国药准字HJ20250082 | BRAFTOVI 恩考芬尼胶囊 | 2030-06-29 | 2029-12-29 |
| 国药准字HJ20260054 | MEKTOVI 贝美替尼片 | 2031-06-02 | 2030-12-02 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.